Barclays
CLB icon

Barclays’s Core Laboratories CLB Stock Holding History

Barclays’s Portfolio CLB Stock Details CLB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-12,200
Closed -$126K – 5630
2020
Q1 		$126K Buy
12,200
+1,100
+10% +$30.8K ﹤0.01% 4630
2019
Q4 		$418K Buy
11,100
+7,600
+217% +$341K ﹤0.01% 4448
2019
Q3 		$163K Sell
3,500
-3,200
-48% -$149K ﹤0.01% 5115
2019
Q2 		$350K Sell
6,700
-3,900
-37% -$229K ﹤0.01% 4638
2019
Q1 		$731K Buy
10,600
+1,600
+18% +$107K ﹤0.01% 3744
2018
Q4 		$537K Buy
9,000
+5,000
+125% +$431K ﹤0.01% 3737
2018
Q3 		$463K Sell
4,000
-35,700
-90% -$4.03M ﹤0.01% 4336
2018
Q2 		$5.01M Buy
39,700
+34,300
+635% +$4.17M ﹤0.01% 1726
2018
Q1 		$584K Sell
5,400
-12,000
-69% -$1.33M ﹤0.01% 3816
2017
Q4 		$1.91M Buy
17,400
+14,400
+480% +$1.44M ﹤0.01% 2475
2017
Q3 		$296K Buy
3,000
+1,600
+114% +$155K ﹤0.01% 4089
2017
Q2 		$142K Sell
1,400
-3,300
-70% -$356K ﹤0.01% 4645
2017
Q1 		$543K Sell
4,700
-30,400
-87% -$3.53M ﹤0.01% 3318
2016
Q4 		$4.21M Buy
35,100
+30,100
+602% +$3.33M ﹤0.01% 1517
2016
Q3 		$562K Sell
5,000
-5,600
-53% -$645K ﹤0.01% 3123
2016
Q2 		$1.31M Sell
10,600
-24,900
-70% -$3.01M ﹤0.01% 2375
2016
Q1 		$3.98M Buy
35,500
+24,900
+235% +$2.59M 0.01% 1357
2015
Q4 		$1.14M Sell
10,600
-5,900
-36% -$675K ﹤0.01% 2488
2015
Q3 		$1.63M Buy
16,500
+4,800
+41% +$522K ﹤0.01% 2293
2015
Q2 		$1.33M Buy
11,700
+1,300
+13% +$158K ﹤0.01% 2617
2015
Q1 		$1.08M Buy
10,400
+5,200
+100% +$554K ﹤0.01% 2894
2014
Q4 		$624K Sell
5,200
-17,800
-77% -$2.34M ﹤0.01% 3645
2014
Q3 		$3.36M Buy
23,000
+9,100
+65% +$1.4M ﹤0.01% 2168
2014
Q2 		$2.32M Buy
13,900
+12,200
+718% +$2.17M ﹤0.01% 2447
2014
Q1 		$337K Buy
1,700
+1,000
+143% +$189K ﹤0.01% 4278
2013
Q4 		$133K Sell
700
-900
-56% -$167K ﹤0.01% 5387
2013
Q3 		$271K Sell
1,600
-4,100
-72% -$636K ﹤0.01% 4747
2013
Q2 		$864K Buy
+5,700
New +$808K ﹤0.01% 3567

Other funds holding CLB

Ariel Investments
Ariel Investments Chicago, Illinois $9.6B AUM 22.21% 1-Year Est. Return
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $25.4B AUM 35.48% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
GJL
Gendell Jeffrey L $9.6B AUM 75.6% 1-Year Est. Return
Heartland Advisors
Heartland Advisors Milwaukee, Wisconsin $2.08B AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.96T AUM 27.49% 1-Year Est. Return

Barclays's CLB Position: Q3 2026 in Review

Barclays increased its Core Laboratories (CLB) stake by 54% in Q3 2026, buying an estimated $144K and bringing the position to 35,540 shares worth $345K. The position accounts for ﹤0.01% of the portfolio, ranked #3670.

Barclays first reported a position in CLB in Q2 2013 and has held it in 53 quarters since. The position peaked at $36M in Q2 2018. 131 funds tracked by Wall St. Rank hold CLB as of Q3 2026.

  • Barclays held 35,540 shares of Core Laboratories worth $345K as of Q3 2026.
  • Barclays bought 12,400 Core Laboratories shares in Q3 2026, an estimated $144K.
  • Core Laboratories made up ﹤0.01% of Barclays's portfolio in Q3 2026, its #3670 holding.
  • Barclays first reported a position in Core Laboratories in Q2 2013 and has held it in 53 quarters since.
  • Barclays's Core Laboratories position peaked at $36M in Q2 2018.
  • 131 funds tracked by Wall St. Rank held Core Laboratories as of Q3 2026.

Based on Barclays's 13F filing for Q3 2026, filed 6 Nov 2026.